Literature DB >> 17143514

Immunohistochemical demonstration of the zinc metalloprotease insulin-degrading enzyme in normal and malignant human breast: correlation with tissue insulin levels.

Razvan T Radulescu1, Carla Hufnagel, Peter Luppa, Heide Hellebrand, Wen-Liang Kuo, Marsha Rich Rosner, Nadia Harbeck, Cecylia Giersig, Alfons Meindl, Manfred Schmitt, Gregor Weirich.   

Abstract

Insulin is a hormone crucial to metabolism and an essential growth factor for normal and neoplastic tissues. We have now determined insulin in extracts of 23 primary breast cancer specimens and of non-neoplastic breast tissues by a chemiluminescent immunoassay. Remarkably, insulin was measured only in grade 3 tumors, whereas grade 2 carcinomas and the normal mammary gland were each insulin-negative. We also performed immunohistochemistry for insulin-degrading enzyme (IDE), a cytoplasmic zinc metalloprotease belonging to the inverzincin family and participating in insulin cleavage. IDE was detected in most insulin-positive grade 3 carcinomas, indicating that it might be dysfunctional in these anaplastic tumors. IDE was equally present in the insulin-negative grade 2 carcinomas. Moreover, five grade 3 carcinomas and one grade 2 carcinoma displayed a loss of heterozygosity in the 10q chromosomal region harboring the IDE gene, but, despite these alterations, IDE was detected immunohistochemically, indicating a retention of the second allele. Compared to the expression of IDE in 92% of the tumors examined, only 57% of 21 normal breast specimens stained positively for IDE. In contrast to this increase in IDE-positive epithelial cells in breast cancer vs. normal breast, additional immunohistochemical analysis of 17 node-positive breast carcinomas and corresponding tumor-bearing lymph nodes showed that IDE expression decreases from primary tumor to lymph node metastasis. Altogether, this study represents the first demonstration of IDE in normal and neoplastic human mammary tissues. Our present report should also provide an experimental starting point towards exploring a potential role of IDE in the control of tumor progression.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17143514

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  6 in total

1.  Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.

Authors:  Christina Yfanti; Karin Mengele; Apostolos Gkazepis; Gregor Weirich; Cecylia Giersig; Wen-Liang Kuo; Wei-Jen Tang; Marsha Rosner; Manfred Schmitt
Journal:  Int J Mol Med       Date:  2008-10       Impact factor: 4.101

2.  Intracellular insulin in human tumors: examples and implications.

Authors:  Razvan T Radulescu
Journal:  Diabetol Metab Syndr       Date:  2011-04-01       Impact factor: 3.320

3.  Immunohistochemical evidence of ubiquitous distribution of the metalloendoprotease insulin-degrading enzyme (IDE; insulysin) in human non-malignant tissues and tumor cell lines.

Authors:  Gregor Weirich; Karin Mengele; Christina Yfanti; Apostolos Gkazepis; Daniela Hellmann; Anita Welk; Cecylia Giersig; Wen-Liang Kuo; Marsha Rich Rosner; Wei-Jen Tang; Manfred Schmitt
Journal:  Biol Chem       Date:  2008-11       Impact factor: 3.915

Review 4.  Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

Authors:  Laetitia Lesire; Florence Leroux; Rebecca Deprez-Poulain; Benoit Deprez
Journal:  Cells       Date:  2022-04-05       Impact factor: 6.600

Review 5.  Secretory Autophagy and Its Relevance in Metabolic and Degenerative Disease.

Authors:  Claudio Daniel Gonzalez; Roxana Resnik; Maria Ines Vaccaro
Journal:  Front Endocrinol (Lausanne)       Date:  2020-05-05       Impact factor: 5.555

6.  Blocking endogenous peroxidases: a cautionary note for immunohistochemistry.

Authors:  Razvan Tudor Radulescu; Thomas Boenisch
Journal:  J Cell Mol Med       Date:  2007-12-05       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.